Regular Article

British Journal of Cancer (1999) 80, 1979–1981. doi:10.1038/sj.bjc.6690630 www.bjcancer.com
Published online 30 July 1999

Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer

D G Bebb1,2,4, Z Yu1, J Chen1, M Telatar5, K Gelmon2, N Phillips3, R A Gatti5 and B W Glickman1

  1. 1Centre for Environmental Health, Department of Biology, University of Victoria, P.O. Box 3020, Victoria, BC V8W 3N5, Canada
  2. 2Departments of Advanced Therapeutics, British Columbia Cancer Research Centre, 601 W. 10th Avenue, Vancouver, BC V5Z 1L3, Canada
  3. 3Departments of Cancer Control Strategy, British Columbia Cancer Research Centre, 601 W. 10th Avenue, Vancouver, BC V5Z 1L3, Canada
  4. 4Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada
  5. 5Department of Pathology, School of Medicine, University of California, Los Angeles, CA 90095 –1732, USA

Received 24 August 1998; Revised 2 February 1999; Accepted 16 February 1999.

Top

Abstract

Epidemiological evidence points to an increased risk of breast cancer in ataxia telangiectasia (AT) heterozygote women. Previous attempts to screen early onset or familial breast cancer patients failed to confirm an association. The issue of AT and late onset sporadic breast cancer remained unresolved. We screened 47 women who developed later onset, sporadic breast cancer for ataxia telangiectasia mutated (ATM) mutations. No mutations were found.

Keywords:

breast cancer, ataxia telangiectasia, protein truncation test (PTT), cancer predisposition

Top

References

  1. Athma, P., Rappaport, R. & Swift, M. (1996). Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92: 130–134. | Article | PubMed | ISI | ChemPort |
  2. Bebb, G., Steele, P. P., Warrington, P. J., Moffat, J. A. & Glickman, B. W. (1998). Caffeine does not potentiate radiation induced DNA damage in ataxia-telangiectasia lymphoblastoid cells. Mutat Res 401: 27–32.
  3. Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F. & Medows, A. T. (1996). Breast and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334: 745–751. | Article | PubMed | ISI | ChemPort |
  4. Borresen, A. L., Anderson, T. I., Treti, S., Heiberg, A. & Moller, P. (1990). Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer 2: 339–340. | PubMed | ISI | ChemPort |
  5. Broca, P. P. (1866). Traites des tumeurs 1: 80
  6. Chen, J., Birkholtz, G. G., Lindblom, P., Rubio, C. & Lindblom, A. (1998). The role of ataxia-telangiectasia in familial breast cancer. Cancer Res 58: 1376–1379. | PubMed | ISI | ChemPort |
  7. Easton, D. F. (1994). Cancer risks in A-T heterozygotes. Int J Radiat Biol 66: S177–182. | Article | PubMed | ISI | ChemPort |
  8. Fitzgerald, M. G., Bean, J. M., Hegde, S. R., Unsal, H., MacDonald, D. J., Harkin, D. P., Finkelstein, D. M., Isselbacher, K. J. & Haber, D. A. (1997). Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15: 307–310. | Article | PubMed | ISI | ChemPort |
  9. Ford, D. & Easton, D. F. (1995). The genetics of breast and ovarian cancer. Br J Cancer 72: 805–812. | PubMed | ISI | ChemPort |
  10. Gatti, R. A. (1998). Ataxia telangiectasis. In The Genetic Basis of Human Cancers, Vogelstein B, Kingley KW McGraw-Hill: New York 275–300.
  11. Gilad, S., Khosravi, R., Shkedy, D., Uziel, T., Ziv, Y., Savitsky, K., Rotman, G., Smith, S., Chessa, L., Jorgensen, T. J., Harnik, R., Frydman, M., Sanal, O., Portnoi, S., Goldwicz, Z., Jaspers, N. G. J., Gatti, R., Lenoir, G., Lavin, M., Tatsumi, K., Wegner, R. D., Shiloh, Y. & Bar-Shira, A. (1996). Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 5: 433–439. | Article | PubMed | ISI | ChemPort |
  12. Heim, R. A., Lench, N. J. & Swift, M. (1992). Heterozygous manifestations in four autosomal recessive cancer-prone syndromes, ataxia-telangiectasia, xeroderma pigmentosum, Fanconi anemia and Bloom syndrome. Mutat Res 284: 25–36. | Article | PubMed | ISI | ChemPort |
  13. Kinzler, K. W. & Vogelstein, B. (1997). Gatekeepers and caretakers. Nature 386: 761–762. | Article | PubMed | ISI | ChemPort |
  14. Lavin, M. F., Bennett, I., Ramsay, J., Gardiner, R. A., Seymor, G. J., Farrell, A. & Walsh, M. (1994). Identification of a potentially sensitive subgroup among patients with breast cancer. J Natl Cancer Inst 86: 1627–1634.
  15. Lynch, H. T., Mulchahy, G. M. & Lynch, P. (1976). Genetic factors in breast cancer, a survey. Pathol Ann 11: 77–101.
  16. Lynch, H. T., Smyrk, T. & Lynch, J. (1997). An update of HNPCC, Lynch syndrome. Cancer Genet Cytogenet 93: 84–99. | Article | PubMed | ISI | ChemPort |
  17. Norman, A., Iwamoto, K. S., Kagan, A. R. & Wollin, M. (1992). Radiation sensitive breast cancer patients. Radiother Oncol 23: 196–197.
  18. Pippard, E. C., Hall, A. J., Barker, D. J. & Bridges, B. A. (1988). Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 48: 2929–2932. | PubMed | ISI | ChemPort |
  19. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., Ashkenazi, M., Pecker, I., Frydman, M., Harnik, R., Patanjali, S. R., Simmons, A., Clines, G. A., Sartiel, A., Gatti, R. A., Chessa, L., Sanal, O., Lavin, M. F., Jaspers, N. G. J., Taylor, A. M. R., Arlett, C. F., Miki, T., Weissman, S. M., Lovett, M., Collins, F. S. & Shiloh, Y. (1995). A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749–1753. | Article | PubMed | ISI | ChemPort |
  20. Scott, D., Jones, L. A., Elyan, S. A. G., Spreadborough, A., Cowan, R. & Ribiero, G. (1993). Identification of AT-heterozygotes. In Ataxia-Telangiectasia, NATO ASI Series H 77: Gatti RA, Palmer RB (eds.) 101–116.
  21. Scott, D., Barber, J. B. P., Levine, E. L., Burrill, W. & Roberts, S. A. (1998). Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients – a test for predisposition. Br J Cancer 77: 614–620. | PubMed | ISI | ChemPort |
  22. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T. & Livingston, D. M. (1997). Association of Brcal with Rad51 in mitotic and meiotic cells. Cell 88: 265–275. | Article | PubMed | ISI | ChemPort |
  23. Serova, O. M., Mazoyer, S., Puget, N., Dubois, V., Tonin, P., Shugart, Y. Y., Goldgar, D., Narod, S. A., Lynch, H. T. & Lenoirm, G. M. (1997). Mutations in Brcal and Brca2 in breast cancer families, are there more breast cancer-susceptibility genes? Am J Hum Genet 60(3): 486–495. | PubMed | ISI | ChemPort |
  24. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P. & Bradley, A. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386: 804–810. | Article | PubMed | ISI | ChemPort |
  25. Stankovic, T., Kidd, A. M. J., Sutcliffe, A., Mcguire, G. M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A. R., Easton, D. F., Lennox, G. G., Haites, N., Byrd, P. J. & Taylor, A. M. R. (1998). ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles – expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am J Hum Genet 62: 334–345. | Article | PubMed | ISI | ChemPort |
  26. Swift, M., Sholman, L., Perry, M. & Chase, C. (1976). Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 36: 209–215. | PubMed | ISI | ChemPort |
  27. Swift, M., Morrell, D., Massey, R. B. & Chase, C. L. (1991). Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831–1836. | PubMed | ISI | ChemPort |
  28. Telatar, M., Wang, Z., Udar, N., Liang, T., Bernatowska-Matuszkewicz, E., Lavin, M., Shiloh, Y., Concannon, P., Good, R. A. & Gatti, R. A. (1996). Ataxia-telangiectasia, mutations in ATM cDNA detected by protein truncation screening. Am J Hum Genet 59: 40–44. | PubMed | ISI | ChemPort |
  29. Telatar, M., Teraoka, S., Wang, Z. J., Chun, H. H., Liang, T., Castellvibel, S., Udar, N., Borresendale, A. L., Chessa, L., Bernatowska-Matuszkiewicz, E., Porras, O., Watanabe, M., Junder, A., Concannon, P. & Gatti, R. A. (1998). Ataxia-telangiectasia – identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 62: 86–97.
  30. Telatar, M., Wang, Z., Castellvi-Bel, S., Tai, L-Q, Rivero-Carmena, M., Regueiro, J. R., Porras, O. & Gatti, R. A. (1999). A model for ATM heterozygote identification in a large population, Four founder effect ATM mutations identify most of Costa Rican patients with ataxia-telangiectasia. Mol Genet Metab, (in press)
  31. Tokunga, M., Land, C. E. & Yamamoto, T. (1987). Incidence of breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1980. Radiat Res 112: 243–272.
  32. Vorechovsky, I., Luo, L., Dyer, M. J. S., Catovsky, D., Amlot, P., Yaxley, J. C., Foroni, L., Hammarstrom, L., Webster, A. D. B. & Yuille, M. (1997). Clustering of missense mutations in the ataxia-telangiectasia gene in sporadic T-cell leukaemia. Nat Genet 17: 96–99. | Article | PubMed | ISI | ChemPort |
  33. Yuille, M. A. R., Coignet, L. J. A., Abraham, S. M., Yaqub, F., Luo, L., Matutes, E., Britobabapulle, V., Vorechovsky, I., Dyer, M. J. S. & Catovsky, D. (1998). ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene 16: 789–796. | Article | PubMed | ISI | ChemPort |